Predictions
Emerald Health Therapeutics Inc
Start price
Target price
Perf. (%)
€0.13
08.07.21
08.07.21
-
08.07.22
08.07.22
-77.81%
08.07.22
08.07.22
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€2.39
08.07.21
08.07.21
-
08.07.22
08.07.22
13.98%
08.07.22
08.07.22
Antibe Therapeutics Inc.
Start price
Target price
Perf. (%)
€2.48
08.07.21
08.07.21
-
08.07.22
08.07.22
-80.56%
21.05.22
21.05.22
Aptose Biosciences
Start price
Target price
Perf. (%)
€3.22
11.06.21
11.06.21
€4.00
11.06.22
11.06.22
-69.57%
14.12.21
14.12.21
Could be worthwhile Investment >10% per year
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€9.52
27.05.21
27.05.21
€32.00
27.05.22
27.05.22
-55.61%
28.05.22
28.05.22
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth >5% per year expected
Very Future proof/growth oriented business model
Aptose Biosciences
Start price
Target price
Perf. (%)
€4.64
01.05.21
01.05.21
€4.50
01.05.22
01.05.22
-30.60%
11.06.21
11.06.21
Could be worthwhile Investment >10% per year
Aphria Inc.
Start price
Target price
Perf. (%)
€16.47
19.03.21
19.03.21
€13.00
19.03.22
19.03.22
-22.87%
20.02.22
20.02.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Organigram Holdings Inc.
Start price
Target price
Perf. (%)
€13.28
12.03.21
12.03.21
€24.00
12.03.22
12.03.22
-62.26%
12.03.22
12.03.22
Could be very worthwhile Investment >20% year
Aphria Inc.
Start price
Target price
Perf. (%)
€13.38
08.03.21
08.03.21
€15.00
13.62%
10.03.21
10.03.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
LexaGene Holdings Inc.
Start price
Target price
Perf. (%)
€0.92
11.02.21
11.02.21
€2.00
11.02.22
11.02.22
-52.92%
20.04.21
20.04.21
Aphria Inc.
Start price
Target price
Perf. (%)
€20.95
10.02.21
10.02.21
€22.00
11.75%
11.02.21
11.02.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Canopy Growth Corp
Start price
Target price
Perf. (%)
€36.00
07.02.21
07.02.21
-
07.02.22
07.02.22
-80.67%
08.02.22
08.02.22
Probably not worthwhile Investment
High risks for its business
Few uniques
Aphria Inc.
Start price
Target price
Perf. (%)
€9.43
14.01.21
14.01.21
€28.00
72.92%
12.03.21
12.03.21
Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
Aphria Inc.
Start price
Target price
Perf. (%)
€7.48
11.01.21
11.01.21
-
11.01.22
11.01.22
39.14%
15.01.21
15.01.21
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Burcon Nutrascience Corp.
Start price
Target price
Perf. (%)
€2.81
10.01.21
10.01.21
-
10.01.22
10.01.22
7.84%
23.01.21
23.01.21
Risky Investment
Neptune Wellness Solutions Inc
Start price
Target price
Perf. (%)
€60.55
16.11.20
16.11.20
€105.00
16.11.21
16.11.21
-10.40%
28.11.20
28.11.20
Could be worthwhile Investment >10% per year
Good rating
Differentiated customer and product portfolio
Risky balance sheet
Aphria Inc.
Start price
Target price
Perf. (%)
€4.90
14.11.20
14.11.20
-
14.11.21
14.11.21
23.24%
27.11.20
27.11.20
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Standard Investments for future growth
High dividend yield expected
Aphria Inc.
Start price
Target price
Perf. (%)
€5.20
07.11.20
07.11.20
€6.40
23.49%
30.11.20
30.11.20
Could be worthwhile Investment >10% per year
Very Future proof/growth oriented business model
Revenue growth >5% per year expected
Aphria Inc.
Start price
Target price
Perf. (%)
€4.70
05.11.20
05.11.20
-
05.11.21
05.11.21
170.32%
06.11.21
06.11.21
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Edesa Biotech Inc
Start price
Target price
Perf. (%)
€6.15
21.09.20
21.09.20
€4.00
04.11.21
04.11.21
17.07%
05.11.21
05.11.21
Probably not worthwhile Investment
High valuation
Trillium Therapeutics
Start price
Target price
Perf. (%)
€8.28
07.09.20
07.09.20
-
04.11.21
04.11.21
-21.91%
15.07.21
15.07.21
Could be very worthwhile Investment >20% year
